SAN DIEGO, October 2nd, 2017 – Sergey Bugrov, Executive Director of Global Discovery at ChemDiv, delivered two lectures entitled “Diverse Discovery Libraries and How They Can be Used in Research” at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM) and at the IHuman Institute of the ShanghaiTech University.
The lectures were dedicated to one of the most important steps in the process of drug discovery – the project-based selection of compounds. Choosing the right compounds amongst the many millions available in numerous libraries is essential for the success of a discovery project, and Dr. Bugrov, having distilled his extensive experience in the field of drug discovery, presented a number of effective strategies for compound selection and their application in research programs.
ChemDiv is a recognized global leader in discovery chemistry with one of the industry’s largest, most diverse, and most productive collections of over 1,600,000 lead-like small molecules. Over the past 25+ years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, immunology, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv’s integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond.
About IHuman Institute
The iHuman Institute is an international research effort on the campus of ShanghaiTech University. The institute is a gateway to the exciting world of Shanghai life science research. What makes the iHuman Institute unique is its focus on integrating data across the different spatial and temporal scales to build an atomic resolution model of the human body to better understand disease and develop next generation better and safer medicines.
Shanghai Institute of Materia Medica (hereafter referred as SIMM), Chinese Academy of Sciences (hereafter referred as CAS), has the longest history as a comprehensive research institution for drug discovery in China. In line with the mission of “Discovering new drugs to relieve patients suffering from various diseases”, SIMM has developed and commercialized over 100 new drugs in the past 80 years. Among them, a number of innovative drugs, such as Artemether, Dimercaptosuccinic acid, and Huperzine A, etc., have gained domestic and abroad recognitions. Recent years SIMM have witnessed the development of some novel drugs, including Depsides salts, a modern Traditional Chinese Medicine (TCM), and Antofloxacin Hydrochloride, a novel fluoroquinolone antibacterial agent. Currently, SIMM has a number of candidates in clinical stages.